Pharmaron Beijing Co., Ltd. Stocks

Pharmaron Beijing Co., Ltd., along with its affiliated entities, delivers comprehensive pharmaceutical research and development solutions to the global life sciences sector. Its operations span North America, Europe, mainland China, other parts of Asia, and various international markets. The company categorizes its extensive offerings into five primary divisions: Laboratory Services; Chemistry, Manufacturing, and Controls (CMC) Services; Clinical Development Services; Biologics and Cell and Gene Therapy Services; and other miscellaneous services. Through its Laboratory Services division, Pharmaron supports early drug discovery with services encompassing medicinal, synthetic, and analytical chemistry, as well as computer-aided drug design (CADD). It further provides bioscience capabilities, including in vitro and in vivo drug metabolism, pharmacokinetics (DMPK) and ADME solutions, in vitro biology, in vivo pharmacology, safety assessment studies, and specialized U.S.-based laboratory support. Additionally, the company offers expertise in process development and manufacturing, material science and pre-formulation, formulation development and manufacturing, and analytical method development. Its Clinical Development Services include radiolabelled science, early-phase clinical trials, clinical research coordination, and site management. Pharmaron also functions as a contract research, development, and manufacturing organization (CRDMO) for pharmaceutical products, complementing its business development support. Established in 2004, the firm maintains its corporate headquarters in Beijing, People's Republic of China.